Contract analysis

I. Executive Summary This memorandum constitutes an internal analysis evaluating the indemnification provisions negotiated in the Exclusive License Agreement (the "License Agreement") for the out-license of PPC-4187 (Penteracitinib), a selective Janus kinase 1 (JAK1) inhibitor currently in clinical development for the treatment of moderate-to-severe atopic dermatitis, from Penterra Pharmaceuticals Corp. ("Penterra" o

II. Overview of the Indemnification Framework The License Agreement contains a mutual indemnification structure that is standard for pharmaceutical out-license transactions of this scale and complexity. The indemnification provisions are set forth primarily in Article 14 of the License Agreement (Sections 14.1 through 14.9), with related definitions appearing in Article 1 and supplementary provisions appearing in the

III. Penterra's Indemnification Obligations (Licensor Indemnification) A. Scope of Coverage

Section 14.1 of the License Agreement provides that Penterra shall indemnify, defend, and hold harmless Meridian and its Affiliates — including Meridian Pharma (Shanghai) Co., Ltd., Meridian Japan K.K., Meridian Korea Inc., and Meridian Bio Australia Pty Ltd — and their respective officers, directors, employees, and agents (collectively, the "Meridian Indemnitees") from and against any and all Losses (as defined in S

1. Breach of Representations and Warranties Made by Penterra. Penterra has made a series of representations and warranties in Article 10 of the License Agreement, each of which, if breached, would trigger an indemnification obligation in favor of the Meridian Indemnitees. These representations include, without limitation: (a) Due Organization and Good Standing. Penterra is duly organized, validly existing, and in goo

2. Penterra's Negligence or Willful Misconduct. Penterra's indemnification obligation extends to Losses arising from the negligence or willful misconduct of Penterra, its officers, employees, and agents in connection with the performance of Penterra's obligations under the License Agreement and the ancillary agreements, including the Supply Agreement, the Technology Transfer Agreement, and the Quality Agreement. This

3. Third-Party IP Infringement Claims. Section 14.1(c) of the License Agreement provides that Penterra shall indemnify the Meridian Indemnitees against any claim, action, or proceeding brought by any third party alleging that the Licensed IP, as existing on the Effective Date, infringes, misappropriates, or otherwise violates any intellectual property right of such third party. This indemnity is specifically directed

4. Manufacture or Supply of Clinical Supply Material. Penterra's indemnification obligation covers Losses arising from Penterra's supply of active pharmaceutical ingredient (API) and reference standard materials to Meridian under the Supply Agreement. Under the current terms of the Supply Agreement, Penterra will supply API to Meridian at cost plus a 15% margin for the first three (3) years following the Effective Da

IV. Meridian's Indemnification Obligations (Licensee Indemnification) A. Scope of Coverage

Section 14.2 of the License Agreement provides that Meridian shall indemnify, defend, and hold harmless Penterra and its Affiliates and their respective officers, directors, employees, and agents (collectively, the "Penterra Indemnitees") from and against any and all Losses arising out of or resulting from the following categories of covered events:

1. Breach of Representations and Warranties Made by Meridian. Meridian has made a series of representations and warranties in Article 10 of the License Agreement, including: (a) Due Organization and Good Standing. Meridian is duly organized and validly existing under the laws of the Hong Kong Special Administrative Region of the People's Republic of China (HK Company Reg. No. 2847631), with full corporate power and a

2. Meridian's Development, Manufacture, or Commercialization of Licensed Products in the Territory. This is the broadest of Meridian's indemnification triggers and covers all activities conducted by Meridian, its Affiliates, and its sublicensees in connection with the development, manufacture (following technology transfer), regulatory approval, marketing, distribution, sale, and post-market surveillance of Licensed

3. Meridian's Negligence or Willful Misconduct. Meridian's indemnification obligation extends to Losses arising from the negligence or willful misconduct of Meridian, its Affiliates (including Meridian Pharma (Shanghai) Co., Ltd., Meridian Japan K.K., Meridian Korea Inc., and Meridian Bio Australia Pty Ltd), its sublicensees, and their respective officers, directors, employees, and agents. This trigger parallels Pent

4. Product Liability Claims from Commercial Sales in the Territory. Meridian's indemnification obligation expressly covers personal injury, death, property damage, or other product liability claims arising from the sale, distribution, administration, or use of PPC-4187 — whether marketed under the PENTECLAR trade name or any other trade name approved for use in a Territory jurisdiction — in the Territory. This trigge

V. Financial Limitations on Indemnification A. Aggregate Liability Cap

Section 14.5(a) of the License Agreement establishes an aggregate liability cap on each party's indemnification obligations. The cap is formulated as follows: each party's aggregate indemnification liability under Article 14 shall not exceed an amount equal to two hundred percent (200%) of the total payments actually received by Penterra under the License Agreement as of the date on which a claim for indemnification

Section 14.5(b) of the License Agreement establishes a per-claim de minimis threshold of $150,000. Under this provision, no indemnification obligation arises with respect to any individual Loss unless the amount of that individual Loss exceeds $150,000. Claims that fall below the de minimis threshold are excluded entirely from the indemnification framework — they do not give rise to any indemnification obligation, an

Section 14.5(c) of the License Agreement establishes an aggregate deductible basket of $750,000. Even where individual claims exceed the $150,000 de minimis threshold and thus qualify as indemnifiable losses, the indemnifying party's indemnification obligations do not attach until the aggregate amount of all qualifying losses exceeds $750,000. Critically, the basket is structured as a "tipping basket" (also referred

VI. Carve-Outs from Financial Limitations

Section 14.6 of the License Agreement identifies three categories of liability that are carved out from the financial limitations described in Section V above. Each carve-out is analyzed below. A. Fraud. The aggregate liability cap, de minimis threshold, and deductible basket do not apply to any Losses arising from or attributable to fraud committed by either party. This is a market-standard carve-out, universally in

VII. Procedural Requirements for Indemnification Claims The License Agreement sets forth detailed procedural requirements governing the assertion, investigation, and resolution of indemnification claims. These procedural provisions are set forth in Section 14.3 (Notice), Section 14.4 (Defense of Third-Party Claims), and Section 14.7 (Cooperation) of the License Agreement. Compliance with these procedures is a conditi

Section 14.3 provides that any party seeking indemnification (the "Indemnified Party") must provide prompt written notice to the party from whom indemnification is sought (the "Indemnifying Party") upon becoming aware of any claim, action, suit, proceeding, investigation, demand, or other circumstance that may reasonably be expected to give rise to an indemnification obligation under Article 14. This notice requireme

Section 14.4 addresses the allocation of responsibility for the defense of third-party claims. The Indemnifying Party has the right, but not the obligation, to assume control of the investigation and defense of any third-party claim for which indemnification is sought, including the selection of counsel, the development of defense strategy, and the conduct of all proceedings related to the claim. Upon assuming contro

VIII. Interaction with Other Agreement Provisions The indemnification provisions do not operate in isolation but interact with several other provisions of the License Agreement and the ancillary agreements. This section analyzes the most significant interactions. A. Interaction with Insurance Requirements

Section 12.4 of the License Agreement requires Meridian to obtain and maintain, at its own cost, product liability insurance and clinical trial insurance throughout the term of the License Agreement, with coverage limits and terms reasonably acceptable to Penterra. Meridian has obtained initial coverage from Jade Dragon Insurance Limited, a Hong Kong-based specialty insurer, with Christine A. Lo serving as the design